Eric Savier, Federica Dondero, Eric Vibert, Daniel Eyraud, Hélène Brisson, Bruno Riou, Fabienne Fieux, Salima Naili‐Kortaia, Denis Castaing, Jean‐Jacques Rouby, Olivier Langeron, Safi Dokmak, Laurent Hannoun, Jean‐Christophe Vaillant, the Donation After Cardiac Death Study Group – 10 April 2015 – Organ donation after unexpected cardiac death [type 2 donation after cardiac death (DCD)] is currently authorized in France and has been since 2006. Following the Spanish experience, a national protocol was established to perform liver transplantation (LT) with type 2 DCD donors.

Santiago J. Munoz – 10 April 2015

Jan Knaak, Mark McVey, Fateh Bazerbachi, Nicolás Goldaracena, Vinzent Spetzler, Nazia Selzner, Mark Cattral, Paul Greig, Les Lilly, Ian McGilvray, Gary Levy, Anand Ghanekar, Eberhard Renner, David Grant, Laura Hawryluck, Markus Selzner – 10 April 2015 – Data regarding transplantation outcomes in ventilated intensive care unit (ICU)–dependent patients with end‐stage liver disease (ESLD) are conflicting. This single‐center cohort study investigated the outcomes of patients with ESLD who were intubated with mechanical support before liver transplantation (LT).

Dechun Feng, Mingjiang Xu, Bin Gao – 10 April 2015

Aurelie Gineste, Patricia Martin, Eric Oswald, Hélène Coppin, Marie‐Paule Roth – 10 April 2015

Kenneth Hung, Jane Gralla, Jennifer L. Dodge, Kiran M. Bambha, Melisa Dirchwolf, Hugo R. Rosen, Scott W. Biggins – 10 April 2015 – Repeat liver transplantation (LT) is controversial because of inferior outcomes versus primary LT. A minimum 1‐year expected post–re‐LT survival of 50% has been proposed. We aimed to identify combinations of Model for End‐Stage Liver Disease (MELD), donor risk index (DRI), and recipient characteristics achieving this graft survival threshold.

Julie Heimbach, Eleonora Terzi – 10 April 2015

Salvatore Petta, Marcello Maida, Fabio Salvatore Macaluso, Vito Di Marco, Calogero Cammà, Daniela Cabibi, Antonio Craxì – 9 April 2015 – In nonalcoholic fatty liver disease, the influence of severity of steatosis on liver stiffness measurement (LSM) is poorly studied and still debated. We assessed the impact of steatosis severity and its ultrasonographic (US) sign, severe bright liver echo pattern, on LSM values and on transient elastography accuracy for the diagnosis of liver fibrosis in a cohort of consecutive patients with nonalcoholic fatty liver disease.

Ping‐I Hsu, Kwok‐Hung Lai, Jin‐Shiung Cheng, Sung‐Shuo Kao, Yuan‐Rung Li, Wei‐Chih Sun, Wen‐Chi Chen, Kung‐Hung Lin, Chih‐An Shin, Po‐Hung Chiang, Yun‐Da Li, Wei‐Ting Ou, Hui‐Chun Chen, Hsien‐Chung Yu – 9 April 2015 – Reactivation of hepatitis B viral (HBV) infection in cancer patients undergoing chemotherapy may cause interruption of chemotherapy and lead to liver failure and death. In our institute, a computerized order entry–based alert system was introduced in September 2011 to remind healthcare providers of HBV testing when prescribing chemotherapy.

Sharon C. Cunningham, Susan M. Siew, Claus V. Hallwirth, Christine Bolitho, Natsuki Sasaki, Gagan Garg, Iacovos P. Michael, Nicola A. Hetherington, Kevin Carpenter, Gustavo de Alencastro, Andras Nagy, Ian E. Alexander – 9 April 2015 – Liver‐targeted gene therapy based on recombinant adeno‐associated viral vectors (rAAV) shows promising therapeutic efficacy in animal models and adult‐focused clinical trials.